Financial Advocates Investment Management Has $96,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS)

Financial Advocates Investment Management lifted its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 57.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 106,850 shares of the company’s stock after acquiring an additional 39,000 shares during the quarter. Financial Advocates Investment Management’s holdings in Gossamer Bio were worth $96,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GOSS. Sivia Capital Partners LLC bought a new position in Gossamer Bio during the first quarter worth $29,000. SG Americas Securities LLC bought a new stake in shares of Gossamer Bio during the 1st quarter worth about $34,000. Sequoia Financial Advisors LLC grew its stake in Gossamer Bio by 27.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after buying an additional 20,000 shares during the last quarter. Monaco Asset Management SAM bought a new position in Gossamer Bio in the 4th quarter valued at about $256,000. Finally, Victory Capital Management Inc. lifted its position in Gossamer Bio by 1,402.4% during the fourth quarter. Victory Capital Management Inc. now owns 312,357 shares of the company’s stock worth $285,000 after acquiring an additional 291,566 shares during the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Oppenheimer began coverage on Gossamer Bio in a research note on Tuesday, June 25th. They set an “outperform” rating and a $9.00 target price on the stock. The Goldman Sachs Group reiterated a “buy” rating and set a $8.00 price objective on shares of Gossamer Bio in a research report on Monday, June 17th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Friday. Finally, Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $0.88 on Friday. Gossamer Bio, Inc. has a 1 year low of $0.45 and a 1 year high of $1.60. The stock has a market capitalization of $198.58 million, a price-to-earnings ratio of -0.83 and a beta of 1.93. The company has a debt-to-equity ratio of 7.37, a current ratio of 7.13 and a quick ratio of 7.13. The company’s 50 day simple moving average is $0.97 and its 200 day simple moving average is $0.94.

Insider Buying and Selling at Gossamer Bio

In other Gossamer Bio news, CEO Faheem Hasnain acquired 372,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was acquired at an average cost of $0.67 per share, for a total transaction of $249,240.00. Following the transaction, the chief executive officer now directly owns 5,408,073 shares in the company, valued at $3,623,408.91. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.00% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.